Rebecca Kristeleit, BSc, PhD

home / authors / rebecca-kristeleit-bsc-phd

Articles

Rebecca Kristeleit, BSc, MBChB, MRCP, PhD

Dr Kristeleit on the Implications of Long-Term Data With Rucaparib in Advanced Ovarian Cancer

April 23rd 2024

Rebecca Kristeleit, BSc, MBChB, MRCP, PhD, discusses the ATHENA-MONO trial in newly diagnosed patients with advanced ovarian cancer.

Dr Kristeleit on the ATHENA-MONO Trial in Ovarian Cancer

April 17th 2024

Rebecca Kristeleit, BSc, MBChB, MRCP, PhD, discusses the phase 3 ATHENA-MONO trial in newly diagnosed patients with advanced ovarian cancer.

Dr Kristeleit on 3-Year Follow-up Data for Rucaparib Maintenance in Ovarian Cancer

April 5th 2024

Rebecca Kristeleit, BSc, MBChB, MRCP, PhD, on efficacy outcomes from the 3-year follow-up for patients with advanced ovarian cancer in the ATHENA-MONO study.

Dr. Kristeleit on QoL With Dostarlimab in dMMR/MSI-H Endometrial Cancer

September 30th 2020

Rebecca Kristeleit, BSc, MBChB, MRCP, PhD, discusses the importance of patient-reported outcomes in the phase 1 GARNET trial in advanced or recurrent mismatch repair deficient/microsatelite instability-high endometrial cancer.

Dr. Kristeleit on the Safety Profile of Rucaparib in Ovarian Cancer

January 18th 2017

Rebecca Kristeleit, BSc, PhD, consultant medical oncologist, University College-London Cancer Institute, discusses the safety profile of rucaparib in the treatment of patients with ovarian cancer.

Dr. Kristeleit on the Efficacy of Rucaparib in Ovarian Cancer

January 10th 2017

Rebecca Kristeleit, BSc, PhD, consultant medical oncologist, University College-London Cancer Institute, discusses the efficacy of rucaparib in the treatment of patients with ovarian cancer.